{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:19:58Z","timestamp":1791688798658,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2025.106947","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:41:31Z","timestamp":1766594491000},"page":"106947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world COVID-19 immunity in multiple sclerosis (CoVaR-MS): A longitudinal follow up study"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-2445","authenticated-orcid":false,"given":"Seema","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Banavathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar J","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roby J","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin P","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106947_bib0001","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106947_bib0002","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2025.106947_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ncn3.12561","article-title":"Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic","volume":"10","author":"Baba","year":"2022","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.msard.2025.106947_bib0004","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106947_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102704","article-title":"Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness","volume":"48","author":"Barun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106947_bib0006","unstructured":"COVID-19 cases WHO COVID-19 dashboard. Datadot n.d. https:\/\/data.who.int\/dashboards\/covid19\/cases (accessed July 21, 2025)."},{"key":"10.1016\/j.msard.2025.106947_bib0007","unstructured":"COVID-19 vaccines Treatment summaries | BNF content published by NICE n.d. https:\/\/bnf.nice.org.uk\/treatment-summaries\/covid-19-vaccines\/(accessed July 28, 2025)."},{"key":"10.1016\/j.msard.2025.106947_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106947_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103458","article-title":"Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England","volume":"57","author":"Garjani","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106947_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103155","article-title":"COVID-19 vaccines and multiple sclerosis disease-modifying therapies","volume":"53","author":"Giovannoni","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106947_bib0011","unstructured":"Green book on Immunisation - chapter 14a COVID-19 n.d."},{"key":"10.1016\/j.msard.2025.106947_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103435","article-title":"Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod","volume":"57","author":"Krbot Skori\u0107","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106947_bib0013","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.msard.2025.106947_bib0014","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jnnp-2021-326839","article-title":"Vaccination and multiple sclerosis in the era of the COVID-19 pandemic","volume":"92","author":"Monschein","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106947_bib0015","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/13524585221134216","article-title":"T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy","volume":"29","author":"Reder","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106947_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104484","article-title":"Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators","volume":"70","author":"Sabatino","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106947_bib0017","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156978","article-title":"Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine\u2013induced antibody and T cell immunity and function","volume":"7","author":"Sabatino","year":"2022","journal-title":"JCI Insight."},{"key":"10.1016\/j.msard.2025.106947_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.26251","article-title":"COVID -19 Vaccine Response in People with Multiple Sclerosis","volume":"91","author":"Tallantyre","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106947_bib0019","unstructured":"Trust MS. Covid-19 vaccines and boosters for people with MS | MS Trust n.d. https:\/\/mstrust.org.uk\/a-z\/covid-19-vaccines-and-boosters-people-ms (accessed July 28, 2025)."},{"key":"10.1016\/j.msard.2025.106947_bib0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:54:47Z","timestamp":1780415687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"alternative-id":["S2211034825006856"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106947","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world COVID-19 immunity in multiple sclerosis (CoVaR-MS): A longitudinal follow up study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106947"}}